The stock of Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) has increased by 12.14 when compared to last closing price of 0.65.Despite this, the company has seen a loss of -1.34% in its stock price over the last five trading days. PRNewsWire reported 2024-02-13 that NEW YORK, Feb. 13, 2024 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will provide a corporate update at the 17th Annual European Life Sciences CEO Forum to take place 28 – 29 of February, 2024 in Zurich, Switzerland. Presentation Details Presentation Date: Wednesday, 28th FebruaryTime: 13:40h CETLocation: Panorama Room (Track C), Hilton Zurich Airport Hotel Dr. Stacy Lindborg, Co-CEO of BrainStorm, will also participate in a panel discussion Neuro Advances Panel: Highlighting the Main Opportunities, at 17:20h on February 28.
Is It Worth Investing in Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) Right Now?
Additionally, the 36-month beta value for BCLI is 0.27. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for BCLI is 56.13M and currently, short sellers hold a 1.51% ratio of that float. The average trading volume of BCLI on April 09, 2024 was 955.69K shares.
BCLI’s Market Performance
BCLI’s stock has seen a -1.34% decrease for the week, with a 109.83% rise in the past month and a 156.14% gain in the past quarter. The volatility ratio for the week is 10.72%, and the volatility levels for the past 30 days are at 18.90% for Brainstorm Cell Therapeutics, Inc. The simple moving average for the last 20 days is 43.78% for BCLI’s stock, with a simple moving average of -3.87% for the last 200 days.
Analysts’ Opinion of BCLI
Many brokerage firms have already submitted their reports for BCLI stocks, with Maxim Group repeating the rating for BCLI by listing it as a “Buy.” The predicted price for BCLI in the upcoming period, according to Maxim Group is $12 based on the research report published on February 04, 2021 of the previous year 2021.
Maxim Group gave a rating of “Buy” to BCLI, setting the target price at $6 in the report published on December 19th of the previous year.
BCLI Trading at 74.68% from the 50-Day Moving Average
After a stumble in the market that brought BCLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.36% of loss for the given period.
Volatility was left at 18.90%, however, over the last 30 days, the volatility rate increased by 10.72%, as shares surge +121.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +135.33% upper at present.
During the last 5 trading sessions, BCLI fell by -1.34%, which changed the moving average for the period of 200-days by -67.56% in comparison to the 20-day moving average, which settled at $0.5277. In addition, Brainstorm Cell Therapeutics, Inc. saw 167.40% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCLI starting from Lindborg Stacy, who purchase 11,500 shares at the price of $1.77 back on Sep 01 ’23. After this action, Lindborg Stacy now owns 181,500 shares of Brainstorm Cell Therapeutics, Inc., valued at $20,402 using the latest closing price.
Stock Fundamentals for BCLI
Current profitability levels for the company are sitting at:
- 62.5 for the present operating margin
- 3.03 for the gross margin
The net margin for Brainstorm Cell Therapeutics, Inc. stands at 49.85. The total capital return value is set at 5.97. Equity return is now at value -1121.89, with -271.62 for asset returns.
Based on Brainstorm Cell Therapeutics, Inc. (BCLI), the company’s capital structure generated -0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -33.93. The debt to equity ratio resting at -0.12. The interest coverage ratio of the stock is 233.03.
Currently, EBITDA for the company is -21.17 million with net debt to EBITDA at 0.0. When we switch over and look at the enterprise to sales, we see a ratio of -145.38. The receivables turnover for the company is -6.73for trailing twelve months and the total asset turnover is -0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.24.
Conclusion
In conclusion, Brainstorm Cell Therapeutics, Inc. (BCLI) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
